Time Restricted Eating on Cancer Risk
Part of paid clinical trials in Charleston, South Carolina.
- Sponsor
- Medical University of South Carolina
- Study ID
- NCT05038137
- Status
- Completed
Conditions
- Breast Cancer
- Pre-diabetes
- Time Restricted Feeding
Eligibility Criteria
- Sex
- FEMALE
- Age
- 40 Years - 67 Years
- Healthy Volunteers
- Not accepted
Interventions
- Time restricted feeding — BEHAVIORALParticipants will eat all food during a self selected 8 hour eating window prior to 8:00 PM.
- Control — BEHAVIORALParticipants will have a daily eating period equal to or greater than 12 hours.
Study Details
Participants will be randomly assigned to either the time restricted feeding group with a daily eating period of 8 hours or the control group with a daily eating period of greater than or equal to 12 hours. There are 2 in-person study visits to have blood, urine and vital signs collected and 8 remote or phone visits with a psychologist or dietician to assist with the eating schedule. The study will take last 3 1/2 months.
Key Dates
- Start date
- May 4, 2022
- Status verified
- May 2026
- Primary completion
- Apr 23, 2024
- Completion
- Apr 23, 2024
Study Design
- Enrollment
- 29 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- PREVENTION
Arms
- Experimental: Time restricted feedingdaily eating period of 8 hours, before 8 PM for 12 weeks
- Active Comparator: Controldaily eating period ≥ 12 hours for 12 weeks
Primary Outcome Measure
Change in Advanced Glycation End Products (AGE) as Assessed by Plasma [ Time Frame: Visit 1 (0 weeks), Visit 2 (14 weeks) ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Medical University of South Carolina | Charleston | South Carolina | 29425 | - |
Find similar trials in Charleston, SC
By condition
By specialty
By research site
Related Studies
- MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression ProfilesRecruiting · Agendia · Birmingham, Alabama
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast CancerPHASE3 · Recruiting · Canadian Cancer Trials Group · Fairbanks, Alaska
- Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBCPHASE2 · Recruiting · Dana-Farber Cancer Institute · Stamford, Connecticut